Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress
Capricor presented positive 24-month HOPE-3 open-label extension data showing patients who crossed over from placebo to Deramiocel slowed upper limb decline by 76% versus their own prior year on placebo. Both treatment groups declined more slowly at 24 months than natural history models predict, and the early-start group showed stable decline rates across both years, suggesting a treatment effect rather than time alone.
Key figures
- Drug Name
- Deramiocel (CAP-1002)
- Phase Of Trial
- Phase 3
- Pdufa date
- November 22, 2026
- Trial name
- HOPE-3 open-label extension
- Ole patients
- 98
- Patients enrolled
- 106
- Reduction in decline rate
- 76%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.